How Skin Aging Reveals Systemic Aging — and What We Can Do About It

Skin aging has long been framed as an aesthetic problem, but this comprehensive review reframes it as a clinically significant marker and mediator of systemic biological aging. Published in the Journal of Allergy and Clinical Immunology by researchers at Mount Sinai's Icahn School of Medicine, the paper argues that the skin's visibility and accessibility make it an ideal model for studying — and potentially intervening in — the aging process across the entire body.

The review identifies two broad categories of aging drivers. Intrinsic aging stems from accumulated molecular damage, genomic instability, and the progressive decline of cellular repair machinery. Extrinsic aging is driven by environmental insults such as UV radiation, pollution, and lifestyle factors. Both converge on cellular senescence, in which damaged cells arrest permanently and secrete a cocktail of inflammatory mediators known as the senescence-associated secretory phenotype (SASP). SASP disrupts surrounding tissue, degrades collagen and elastin in the extracellular matrix, impairs stem cell-mediated epidermal renewal, and fuels a state of low-grade chronic inflammation called inflammaging.

As skin aging advances, the consequences become medically serious. Marked epidermal atrophy leads to chronic skin fragility, poor wound healing, and reduced immunosurveillance — leaving older adults substantially more vulnerable to skin infections and injury. These outcomes are directly relevant to healthspan and functional capacity, not merely appearance.

A particularly important insight is the bidirectional crosstalk between skin inflammation and systemic inflammation. The skin does not merely reflect systemic aging passively; inflammatory signals from aged skin may actively accelerate deterioration in other organ systems, and vice versa. This positions anti-aging skin interventions as potential contributors to broader systemic health.

The review surveys emerging therapeutic strategies targeting senescence, SASP, and inflammaging pathways in the skin — including senolytics, anti-inflammatory biologics, and topical interventions — while outlining key gaps in translational and clinical research. Caveats include reliance on abstract-level data only for this summary.